Status:
COMPLETED
Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC)
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Stage IIIA non-small cell lung cancers comprising a mediastinal ganglionic invasion N2 account for 20 to 30% of the NSCLCs. They are almost always potentially resectable, but the results obtained by s...
Detailed Description
These results justify the choice of the study design currently suggested, testing the preoperative feasibility 1. chemotherapy: cisplatin-Gemzar (arm A) or 2. chemoradiotherapy: cisplatin-navelbine-r...
Eligibility Criteria
Inclusion
- Operable and resectable stage IIIA (T1-3, N2) NSCLC
- World Health Organization (WHO) performance status of 1 or less
Exclusion
- Severe cardiac, respiratory, renal or hepatic failure
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00198367
Start Date
January 1 2003
End Date
July 1 2012
Last Update
May 28 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Lyon-Sud - Radiotherapie/Oncologie
Pierre-Bénite, France